VERICITY VERY 深 沪
已收盘 06-28 16:00:00 美东时间
11.43
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 11.43
- 总市值 1.70亿
- 52周最高 12.135
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.70
- 委 比 0.00%
- 总股本 1487.50万
- 历史最高 27.25
- 量 比 0
- 振 幅 0.00%
- 历史最低 3.75
- 每 手 1
- 风险率 0.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AAC TECHNOLOGIES(2018.HK)1H25 PREVIEW:TARIFF WAR NOT REVERSING THE RECOVERY TREND
We expect AAC to deliver strong 1H25 results YoY due to: a) spec upgrade and vo...
07-14 14:02
港股就是你的ATM：A=阿里 T=腾讯 M=小米
来源：陈达美股投资 一、港股已进入技术性牛市，now what… 划重点的重复讲——今年不买港股先输一半。做投资万万不能对“均值回归”的力量一无所知...
07-07 09:09
马斯克炮轰特朗普“债务奴隶制法案”，放话“团灭”支持议员
马斯克疯狂输出，痛批特朗普强推的支出法案将美国拖入“债务奴隶制”，呼吁成立“新政党”，威胁“谁敢支持就让谁初选完蛋”。
07-01 13:00
5天打出24个NDA“王炸”！谁把默沙东逼急了？
（转自：商图药讯） 全球TOP50药企正处在产品力、管线力、适应证拓展能力等多方角力之中。 撰文|Kathy 杀疯了！ 短短一周时间（6月7日-...
06-24 19:30
港股就是你的ATM：A=阿里 T=腾讯 M=小米
一、港股已进入技术性牛市，nowwhat… 划重点的重复讲——今年不买港股先输一半。做投资万万不能对“均值回归”的力量一无所知，此乃投资世界的万有引...
06-16 11:28
生产经营｜外高桥造船11.4万吨阿芙拉型成品油轮“海洋勇气”轮签字交付
5月26日，外高桥造船为希腊Thenamaris公司建造的11.4万吨阿芙拉型成品油轮“海洋勇气（SEABRAVERY）”轮签字交付。Thenamaris公司...
05-27 20:04
EVENTS.COM NAMED GLOBAL PARTNER OF WARNER BROS. DISCOVERY SPORTS' EVENTS DIVISION
Events.com Becomes a Main Partner of the Three Global Competitions Promoted by the Events Division of Warner Bros. Discovery Sports: the WHOOP UCI Mountain Bike World Series, the FIM Enduran...
05-14 20:00
MULTIVIEW LAUNCHES AUDIENCEVIEW: THE ONLY FIRST-PARTY B2B AUDIENCE DISCOVERY PLATFORM FOR ASSOCIATION MEDIA
AI-powered platform provides exclusive reach to 16M+ B2B professionals across 30 industry segments and 850+ accredited associations DALLAS, May 13, 2025 /PRNewswire/ -- Multiview, the leadin...
05-14 03:00
AEP Reports First-Quarter 2025 Earnings, Reaffirms Guidance
AEP completes anticipated equity needs to execute five-year, $54 billion capital investment plan. Company makes progress achieving balanced regulatory outcomes, focuses on needs of states. G...
05-06 18:57
Sarepta Issues Update From Clinical Programs Focused On LGMD Subtypes 2C/R5, 2D/R3, And 2E/R4; FDA Confirmed That Screening, Dosing May Proceed In Study SRP-9005-101 For Lgmd2C/R5
– U.S. FDA has confirmed that screening and dosing may proceed in Study SRP-9005-101 for LGMD2C/R5– Enrollment and dosing completed in Study SRP-9004-102 for
04-15 20:37
